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Background: During high-intensity focused ultrasound (HIFU) surgical procedures, there is a need to rapidly ablate
pathological tissue while minimizing damage to healthy tissue. Current techniques are limited by relatively long
procedure times and risks of off-target heating of healthy tissue. One possible solution is the use of microbubbles,
which can improve the efficiency of thermal energy delivery during HIFU procedures. However, microbubbles also
suffer from limitations such as low spatial selectivity and short circulation time in vivo. In this study, the use of a
dual-perfluorocarbon nanodroplet that can enhance thermal ablation, yet retains high spatial selectivity and circulation
half-life, was evaluated in vivo and compared to traditional microbubble agents during HIFU ablations of rat liver.
Methods: High-intensity focused ultrasound (1.1 MHz, 4.1 MPa, 15-s continuous wave) was applied to rat liver in vivo,
and heating was monitored during sonication by magnetic resonance thermometry. Thermometry data were analyzed
to quantify temperature rise and ablated area, both at the target and prefocally, for HIFU applied 5, 15, or 95 min after
intravenous injection of either nanodroplet or microbubble agents. Sham control experiments (no injected agents)
were also performed.
Results: At all three time points, nanodroplets significantly enhanced thermal delivery to the target, achieving
temperatures 130 % higher and ablated areas 30 times larger than no-agent control sonications. Nanodroplets did not
significantly enhance off-target surface heating. Microbubbles also resulted in significantly greater thermal delivery,
but heating was concentrated at the proximal surface of the animal, causing skin burns. Furthermore, microbubbles
resulted in lower thermal delivery to the desired target than even the control case, with the notable exception of the
95-min time point.
Conclusions: Results indicate that the nanodroplet formulation studied here can substantially increase thermal delivery
at the acoustic focus while avoiding prefocal heating. In contrast, microbubbles resulted in greater prefocal heating
and less heating at the target. Furthermore, nanodroplets are sufficiently stable to enhance HIFU ablation in vivo for
at least 1.5 h after injection. The use of a dual-perfluorocarbon nanodroplet formulation as described herein could
substantially reduce HIFU procedure times without increasing the risk of skin burns.
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High-intensity focused ultrasound (HIFU) can be used
to non-invasively ablate tissue, both benign and malignant.
HIFU is already FDA-approved for ablation of uterine
fibroids, and pre-clinical evaluation of HIFU for the treat-
ment of a variety of tumors, including breast, prostate,
brain, pancreas, bone, and liver, is underway in the US,
Europe, and Asia [1–4]. The clinical applications of HIFU
are expanding, but safety is still a concern. Major obstacles
associated with HIFU tumor ablation are superficial skin
burns and long treatment times [5].
Microbubbles are known to increase the rate of HIFU
ablation by reducing the acoustic energy required to
cause heating and lesion formation [6]. However, micro-
bubbles which are present outside the target region can
lead to heating and/or ablation of healthy tissue outside
the desired treatment area. Microbubbles also have a
relatively short half-life in vivo [7], limiting the time over
which they are effective during a HIFU surgical proced-
ure. Because such procedures can last for several hours,
an agent with a longer effective lifetime is highly desirable.
Moreover, these micron-sized, lipid-shelled gas bubbles
were originally designed as intravenously injectable ultra-
sound contrast agents, and as such, they remain confined
to the vasculature due to their size. An ideal ablation-
enhancing agent would be small enough to extravasate
from blood vessels and accumulate in the target tissue.
Nano-sized bubbles are particularly challenging to pro-
duce and exhibit resonance much higher than typical
HIFU frequencies [8].
Due to the limitations of gas-filled microbubbles in
HIFU applications, emulsions and droplets composed of
various liquid perfluorocarbon agents have been pro-
posed as alternative enhancers of HIFU ablation [9, 10].
Droplets composed of liquid perfluorocarbons can re-
main viable in circulation for substantially longer time
periods than traditional gas-filled agents [11, 12]. Under
sufficient negative pressure, droplets can be vaporized
into microbubbles, a phenomenon often referred to as
acoustic droplet vaporization [13]. The pressure required
to convert liquid droplets into gaseous microbubbles
depends on the size of the droplet and the type of perfluo-
rocarbon utilized, as well as pressure and temperature in
the medium [14–16]. Whether the droplets return to a
liquid state or remain in the gaseous state also depends
on similar parameters.
Much of the previous research on perfluorocarbon
droplets and emulsions has centered on particles in the
micron size range [13, 15, 17–19]; however, these parti-
cles are too large for extravasation. Nanoparticles less
than about 200 nm are typically able to extravasate out
of tumor vasculature due to the enhanced permeability
and retention effect [20], giving them the potential to ac-
cumulate in tumor interstitium. Many of the liquidperfluorocarbon droplets described in previous studies
have been composed of relatively high boiling-point per-
fluorocarbons in order to achieve stability [11, 15, 21, 22].
High boiling-point droplets typically require more acous-
tic energy to induce vaporization. The vaporization
threshold of the droplets can be tailored by carefully
selecting the ratio of perfluorocarbons [16, 23]. Previous
studies in our lab have demonstrated that by combining
two perfluorocarbons (decafluorobutane (C4F10) and
dodecafluoropentane (C5F12)), the energy required to in-
duce vaporization can be lowered while maintaining sub-
stantial stability (≥48 h) at body temperature [9, 24]. We
have also demonstrated in vitro that these nanodroplets
enhance HIFU ablation lesion formation at the target site
whereas microbubbles lead to undesired surface lesion
formation [9].
The goals of the study herein were to (1) evaluate the
ability of our nanodroplet formulation to enhance HIFU
ablation and (2) evaluate their effective lifetime in vivo.
We hypothesized that our nanodroplet formulation
would preferentially enhance HIFU ablation tempera-
tures at the target location compared to microbubbles,
while avoiding unwanted surface heating. Secondly, it
was hypothesized that this enhanced thermal deposition
could be induced over a longer time range following
injection of nanodroplets compared to microbubbles.
These hypotheses were tested in rat liver in vivo using
magnetic resonance (MR) guidance and MR thermom-
etry during HIFU ablation.
Methods
Microbubble and nanodroplet preparation
Microbubbles and nanodroplets were prepared in house.
As previously described [24, 25], lipid-shelled microbub-
bles comprised of decafluorobutane cores were formed
by mechanical agitation, resulting in 2.1 ± 0.5 μm diam-
eter bubbles. Nanodroplet precursors were similarly
formed by mechanical agitation but were comprised of a
1:1 ratio of decafluorobutane and dodecafluoropentane.
These were then condensed under pressure and low
temperature as previously described [24, 26] to result in
240 ± 65 nm diameter droplets. The concentration of
each stock solution was approximately 1 × 1010 agents
per milliliter. For the nanodroplet case, this estimate as-
sumes direct conversion of the precursor microbubbles
into droplets with 100 % efficiency. Both agents were
diluted to 1/5 their original concentration in sterile
saline prior to injection.
MR-guided HIFU application in vivo
The effects of both perfluorocarbon microbubbles and
nanodroplets during HIFU ablation were investigated in
rat liver. The liver was selected because it is relatively
homogeneous and sufficiently large to image with a
Fig. 1 Schematic representation of the rat liver position with respect
to the HIFU transducer. The acoustic focus was positioned ~7 mm
inside the liver. Up to four separate HIFU sonications were performed
in each liver. MR thermometry was performed in a vertical plane
through the HIFU focus for each sonication
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studies were approved by the University of Virginia’s
Institutional Animal Care and Use Committee. Female
Sprague-Dawley rats weighed between 165 and 210 g.
The anterior side of the abdominal region was shaved
and depilated on the day of the experiment. Rats were
initially anesthetized through an intraperitoneal injection
of Ketamine (40 mg/kg, Fort Dodge) and Dexdomitor
(0.2 mg/kg, Pfizer) in sterilized water, and a catheter was
placed in the tail vein. Rats were maintained in an anes-
thetized state using 12.5 mg/kg Nembutal administered
through the tail vein catheter as needed. Microbubbles
or nanodroplets were also administered through the tail
vein catheter.
To investigate the location and degree of the thermal
energy deposited by HIFU, sonication was performed
using an MR-compatible HIFU system (RK-100, FUS
Instruments Inc., Toronto, Ontario) while inside the
bore of a clinical 3 T MRI scanner (Magnetom Trio, Sie-
mens Healthcare, Malvern, PA). The spatial coordinates
of the MRI and HIFU systems were synchronized at the
beginning of each MR-guided HIFU session, by using an
MR thermometry pulse sequence with high readout band-
width to measure the location of a focal temperature rise
induced in a hydrogel phantom. This measurement was
performed at least twice, with the imaged slice oriented in
vertical and horizontal planes, to locate the center of the
focal spot along all three principal axes. Following this ini-
tial alignment procedure, the rat was positioned supine
above the upward-facing HIFU transducer but inclined at
a relatively steep angle with respect to horizontal to allow
the vertical ultrasound beam to pass just below the ribs
and into the liver (Fig. 1). A 2-in. square receive-only RF
coil (FUS Instruments Inc.) was placed around the rat’s
torso to obtain optimum MR signal from the region of
interest. After positioning the animal, multi-plane MR im-
ages of the torso were acquired using a spoiled gradient-
echo pulse sequence with high in-plane resolution (voxel
size 0.33 × 0.33 × 2 mm3). These scout images were used
to identify viable ablation sites with a clear acoustic path
to the transducer unobstructed by ribs or bowel. Up to
four target locations were chosen in each liver (depending
on the available acoustic window), each centered at a
depth of ~7 mm inside the proximal edge of the liver and
all mutually separated by at least 5 mm.
HIFU was applied in conjunction with nanoparticles,
microbubbles, or in the absence of either agent using a
1.14 MHz single-element transducer (75-mm diameter,
F# = 0.8). For this transducer, the transverse and longi-
tudinal dimensions of the acoustic pressure field are 1.5
and 7.6 mm (full-width at half maximum), respectively,
at the ultrasound focus. Because the longitudinal half-
width of the focal spot was nearly 4 mm, a target depth
of 7 mm was chosen to ensure that the focal spot wouldbe contained entirely within the liver. Each administra-
tion of nanodroplets or microbubbles consisted of a
0.l-ml dose of the diluted nanodroplet or microbubble
solution described in the “Microbubble and nanodro-
plet preparation” section injected through the tail vein
catheter, followed by a 0.3-ml heparinized saline flush.
Each nanodroplet/microbubble HIFU application con-
sisted of a 15-s continuous-wave sonication at 15 W of
acoustic power (corresponding to 4.1 MPa peak nega-
tive pressure at the ultrasound focus). For comparison,
sham control experiments were performed by applying
15-s sonications at 15 W in the absence of nanodro-
plets or microbubbles.
This acoustic power and duration were chosen based
on a range of powers and durations that were explored
previously in control animals and in tissue-mimicking
polyacrylamide phantoms containing the same dual-
perfluorocarbon nanodroplets used here [9]. In those
phantom studies, it was found that peak negative pres-
sures above 3 MPa were necessary to create ablation
lesions. Moreover, ablation volume increased with both
pulse length and pressure up to at least 20 s and 4 MPa,
respectively. A 15-s HIFU exposure at 15 W (~4 MPa)
was selected for the present in vivo study because this
combination of duration and power was expected to be
comfortably below the ablation threshold in control
animals but comfortably above the ablation threshold
in treated animals and thus represented a reasonable
choice for demonstrating the potential advantages of
such dual-perfluorocarbon agents.
MR thermometry was performed simultaneously with
ultrasound application as described in the “MR thermometry
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assess thermal enhancement provided by microbubbles
and nanodroplets, only one HIFU application was per-
formed at each target location (either before or after in-
jection of one of these perfluorocarbon agents) and
only one injection was performed in each rat. To assess
the in vivo lifetime of these agents, HIFU was applied
either 5, 15, or 95 min after a single injection. The total
number of 15-s sonications performed across all rats in
conjunction with each perfluorocarbon agent at each
delay time is given in Table 1.
MR thermometry and regional analysis
Dynamic MR thermometry was performed in conjunc-
tion with each sonication, by acquiring a time series of
temperature-sensitive phase images of a single thin slice
through the ultrasound focus using a spoiled gradient-
echo pulse sequence. The measured phase-changes were
then converted into temperature changes using the
standard proton resonance frequency shift method [27,
28]. We were thereby able to monitor the temperature
evolution at each pixel during HIFU application, as has
been previously described in other thermometry studies
[9]. Pulse sequence parameters for these thermometry
scans included: echo time (TE) = 5.0 ms, repetition time
(TR) = 26 ms, flip angle = 20°, readout bandwidth = 219 Hz/
pixel, field of view = 72 × 96 mm2, matrix size = 96 ×
128, slice thickness = 2 mm, in-plane resolution = 0.75 ×
0.75 mm2, temporal resolution = 2.5 s per image.
Images were interpolated by a factor of three in each di-
mension before temperature conversion, yielding 0.25 ×
0.25 mm2 pixels in the temperature maps shown here.
In order to quantify the temperature rise at various
penetration depths within the liver, the thermometry
slice was oriented vertically, parallel to the direction of
the HIFU beam (see Fig. 1). The horizontal position of
this slice was centered on the transverse coordinates of
the ultrasound focus. A high-resolution MR image of
the same slice was also obtained and subsequently fused
with each temperature map, to allow the anatomical lo-
cation of focal heating to be more precisely determined.
Pulse sequence parameters for these high-resolution scans
included: TE = 3.1 ms, TR = 101 ms, flip angle = 50°, read-
out bandwidth = 322 Hz/pixel, field of view = 64 ×
64 mm2, matrix size = 192 × 192, slice thickness = 2 mm,
in-plane resolution = 0.33 × 0.33 mm2, 8 averages, total
scan time = 2 min 35 s.Table 1 Numbers of liver sonications performed for each type
of agent at each time point
Sham Microbubbles Nanodroplets
Time after injection (min) n/a 5 15 95 5 15 95
N 4 4 4 3 5 4 3Each temperature map was analyzed in three different
ways in order to characterize and compare regional vari-
ations in focal heating for each sonication. In the first
analysis, the temperature rise along the beam path was
quantified as a function of depth into the liver (Fig. 2).
This was accomplished by first locating both the hori-
zontal position of the focused ultrasound target and the
proximal margin of the liver by visual inspection of the
high-resolution image. The average temperature rise was
then computed over each 2.5-mm wide horizontal row
of pixels above this margin, centered about the vertical
line passing through the target location. In the second
analysis, the degree of focal heating measured at the tar-
get depth was compared with that measured at the sur-
face. This was accomplished by manually defining two
2.5 × 5.0 mm2 regions of interest, one centered at the
known target location within the liver and the other cen-
tered on the interface between the skin and the proximal
margin of the liver (see Fig. 3a). Thus, the second region
of interest included pixels covering both the skin and
liver near the surface of the animal. The average of the
ten greatest pixel temperatures reached in each region of
interest was calculated. In the third analysis, the ablated
area at the target depth was compared with the ablated
area at the surface of the liver. This was accomplished
by counting the number of pixels within the same regions
of interest described above, for which the measured
temperature rise was at least 23 °C, and multiplying by the
physical area covered by each pixel (0.0625 mm2). Reach-
ing a tissue temperature of 60 °C, or approximately 23°
above body temperature, is generally deemed sufficient to
ensure ablation under the short sonication applied herein
[4]. A two-tailed Student’s t test was applied to determine
the statistical significance of measured differences between
microbubbles, nanodroplets, and sham controls at each
time point. A p value less than 0.05 was considered to be
significant.
Results
In the absence of nanodroplets or microbubbles, HIFU
application for 15 s at 15 W was not sufficient to induce
thermal ablation in the liver, whereas the same ultra-
sound parameters resulted in substantial tissue heating
after intravenous administration of either nanodroplets
or microbubbles. However, the spatial distributions of
the thermal delivery were quite different in all three
cases. The heating profile observed in the sham controls
was relatively even over a range of tissue depths extend-
ing from about 1 to 10 mm, which is commensurate
with the longitudinal extent of the ultrasound focus. In
contrast, the heating profiles observed in the nanodro-
plet and microbubble cases revealed not only greater
heating but more localized heating along the longitu-
dinal beam axis. Nanodroplet-enhanced heating was
Fig. 2 Temperature rise as a function of depth into the liver, calculated from the temperature maps. The heating profiles are plotted versus
depth, with the solid dark line indicating the mean profile averaged over all sonications (n = 3, 4, or 5; see Table 1) performed at a given time
point using a given agent and the pale area indicating a single standard deviation about the mean. Each plot shows the mean heating profile
reached after 15 s of HIFU, applied a 5 min, b 15 min, or c 95 min following injection of microbubbles (MB), nanodroplets (ND), or the sham case
(Control) where no agents were injected (this curve is the same in all three panels)
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from about 4 to 10 mm (spanning the target depth of
7 mm), whereas microbubble-enhanced heating was
concentrated over an even tighter range near the prox-
imal edge of the liver. These data are summarized in
Figs. 2 and 3.
The temperature rise measured as a function of depth
into the liver, averaged over all same-agent HIFU sonica-
tions at a given time point, demonstrated that nanodro-
plets resulted in significantly more heating than the
sham control at the target depth at all time points (5, 15,
or 95 min after injection) (Figs. 2 and 3). The maximal
temperature rise observed after nanodroplets had been
injected was 51.5 ± 12.5 °C and occurred near the target
[i.e., ~7 mm from the liver surface (see Fig. 2)]. This
thermal enhancement was 2.3 times greater than theFig. 3 Maximum temperatures measured at the focal target and at the skin
the corresponding MR image of the rat including the liver. Two regions of
(focus of the HIFU beam), and c the surface of the animal. The gray solid lin
applied without an injection of perfluorocarbon agents (sham control expe
asterisk indicates significance (p < 0.05) compared to the sham control resu
and nanodroplets. The data is displayed as mean ± S.D., where n = 3 to 5temperature rise reached in sham controls, and the cor-
responding ablated area was 31 times larger. The average
maximum temperature rise reached in the sham control
case was 22.4 ± 2.8 °C and occurred at the focal target
region.
Surface heating was minimal in sham controls, only
reaching 13.4 ± 3.6 °C. By comparison, microbubbles
produced significant prefocal heating at the surface,
which coincided with the presence of skin burns ob-
served after the experiment (Figs. 2 and 3c). The
temperature rise observed at the surface was up to 38°
greater than that observed in the sham controls. In con-
trast, nanodroplets resulted in lower, albeit not statisti-
cally significant, heating at the surface compared to
sham controls (Figs. 2 and 3c). At 5- and 15-min time
points, microbubbles resulted in heating at the focus. a The temperature map during a control sonication was overlaid on
interest were defined for quantitative regional analysis: b the target
e indicates the mean temperature change observed when HIFU was
riments), and the dotted lines indicate one standard deviation. The
lts. The dagger indicates significance (p < 0.05) between microbubbles
(see Table 1)
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point that significant target heating was produced by
HIFU in conjunction with microbubbles.
Representative thermal maps, each superimposed on
its corresponding high-resolution anatomic image, are
shown in Fig. 4. The color map threshold in these im-
ages only shows regions where the temperature rise
reached at least 15 °C. These anatomically registered
temperature maps clearly show the prefocal heating
caused by the microbubbles at 5 and 15 min (Fig. 4e–f )
compared to the focal heating produced by the nanodro-
plets (Fig. 4b–c).
For our purposes here, we considered a temperature
rise of 23 °C (corresponding to a nominal temperature
of 60 °C in vivo) to be the threshold for thermal ablation.
This criterion is in line with current clinical practice, in
which the treatment goal is often to reach a temperature
of at least 55–65 °C at the target, depending on the spe-
cific application [4, 29, 30]. According to this criterion,
the nanodroplets resulted in significantly greater abla-
tion areas (13.6 to 19.8 mm2 depending on the time
point) at the focal target location compared to the sham
control (1.0 ± 2.1 mm2, p < 0.01) at every time point in-
vestigated (Fig. 5). The ablation area at the surface was
minimal (no pixels reached 23 °C or more) at each time
point when either HIFU was applied alone (sham control
case) or nanodroplets were present. In comparison, theFig. 4 Example of MRI anatomical images with registered thermal maps. A
onto the MR image. Images are representative MR images of rat livers acqu
representative of the thermal profile observed before any agents were inje
95 min after the injection of nanodroplets (ND). e, f, and g are representati
microbubbles (MB). The white scale bars indicate 1 cm, and the black crosshmicrobubbles resulted in an ablation area at the target
(0.0 to 0.6 mm2) that was not significantly different from
the sham control at 5- or 15-min post injection. With
microbubbles, a significant ablation area was achieved at
the target only at the 95-min time point (see Fig. 5).
Discussion
It is well known that microbubbles can enhance HIFU ab-
lation lesion size and temperature rise; however, since
microbubbles introduced intravascularly are present in
most tissues not only at the acoustic focus but also in the
near field, healthy tissues within the acoustic beam may
also experience heating. Moreover, such prefocal energy
deposition can prevent sufficient ultrasound energy from
reaching the acoustic focus, effectively shielding the
intended target from focal heating. Thus, although prefo-
cal heating is an important safety consideration for all
in vivo HIFU procedures [5], it is of special concern for
microbubble-enhanced ablations. In this study, we dem-
onstrated the advantage of a perfluorocarbon nanodroplet
which remained acoustically inactive (did not enhance
heating) unless exposed to sufficient acoustic pressure to
phase-change into a gas. This allowed us to generate gas-
filled bubbles only at the acoustic focus and thereby only
achieve significant heating enhancement at the target.
Data illustrated that the use of microbubbles produced
greater overall heating than sham controls, but thatll temperature maps were thresholded at 15 °C before overlaying them
ired in a vertical plane passing through the ultrasound focus. a is a
cted. b, c, and d are representatives of the thermal profiles 5, 15, and
ves of the thermal profiles 5, 15, and 95 min after the injection of
airs indicate the intended target location
Fig. 5 Ablation area measured at the focal target and at the skin. Ablation area was quantified by counting the number of image pixels wherein
a temperature rise greater than or equal to 23 °C was measured by MR thermometry following 15 s of HIFU at 15 W. Ablation area was assessed
a at the targeted region (acoustic focus) and b at the surface of the animal. The gray solid line indicates the mean ablation area when HIFU was
applied without injection of any perfluorocarbon agents (sham control experiments), and the dotted lines indicate one standard deviation. The
asterisk indicates significance (p < 0.05) compared to the sham control results. The dagger indicates significance (p < 0.05) between microbubbles
and nanodroplets. The data is displayed as mean ± S.D., where n = 3 to 5 (see Table 1).
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tested resulted in significant prefocal heating at both 5-
and 15-min time points. In fact, each of the animals that
underwent HIFU with microbubbles incurred skin
burns. This was in stark contrast to the nanodroplet-
enhanced HIFU case, where the nanodroplets produced
minimal surface heating even though the focal target
was only ~7 mm from the skin. Moreover, the use of
microbubbles resulted in poor thermal delivery at the
desired target, whereas nanodroplets resulted in signifi-
cant thermal delivery enhancement at the acoustic focus.
In preliminary no-agent, HIFU-only experiments, we
found that substantially greater acoustic power (25 W)
and twice as much time (30 s) was required to induce a
thermal lesion in the liver. These results suggest that the
nanodroplet formulation used here has the potential to
expedite procedure times while avoiding surface heating
associated with injected microbubbles.
The thermal profiles, maximum temperature rise, and
ablated volumes all remained similar for each nanodro-
plet time point from 5- to 95-min post injection, indicat-
ing no loss in ablative properties during this time
window. This result suggests that the nanodroplets re-
main acoustically active in vivo for at least 95 min in the
liver. This longer timeframe would be conducive to en-
abling a single (or very limited number of) injection(s)
for a full HIFU ablation surgery, which can take up to
several hours to complete. However, it will be important
for future studies to investigate the effective lifetime of
these agents in other tissues including tumors.One observation worth noting is that although prior
studies indicated microbubble circulation half-lives in
rats is on the order of minutes [7], our studies demon-
strated that microbubbles contributed to enhanced
HIFU ablation in the liver 95 min after injection. Al-
though lesion size and temperature rises were generally
smaller than those produced by the nanodroplets at this
time point, this result was still surprising as it was not
anticipated that microbubbles would still be acoustically
active after such a long time period. This data suggests
that the lipid encapsulated microbubbles were somehow
preserved in the liver, possibly either by Kupffer cell
phagocytosis [31] or due to mechanical capture within
liver sinusoids [32]. The observation that the depth of
microbubble-induced temperature rise shifted away from
the surface and toward the focal target at later time
points further suggests that prefocal shielding effects be-
come greatly reduced as microbubbles are cleared from
circulation.
By extension, this observation also suggests that prefo-
cal shielding might be reduced at earlier time points by
decreasing the number of microbubbles administered in
the initial injection. However, previous in vitro studies
by our group indicated that significant prefocal heating
could be avoided only by using very low microbubble
concentrations, for which there was also relatively little
thermal enhancement at the target [9]. Hence, whereas
the performance of microbubbles in vivo might be im-
proved somewhat by carefully optimizing the injected
concentration and sonication parameters, we suspect
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robustness and control possible with a phase-change
contrast agent. Such agents are designed to activate only
above a certain pressure threshold, which makes it rela-
tively easy to design a robust sonication protocol that
produces enhanced heating at the ultrasound focus but
avoids unwanted heating elsewhere. Furthermore, be-
cause the activation threshold of the nanodroplets is the-
oretically independent of the agent concentration, their
overall performance should be relatively insensitive to
both the initially injected concentration and its variation
over time.
A limitation of the present study is that our in vivo rat
liver model did not permit sonication at appreciable tis-
sue depths, due to both the small size of the animal and
the limited sonication window accessible between the
between ribs and bowel. Thus, we were unable to ex-
plore larger target depths more in line with eventual
clinical applications. Nonetheless, there is good reason to
expect that nanodroplet-enhanced sonications would per-
form as well or better at deeper target locations. Although
greater ultrasound power would certainly be necessary at
greater target depths, in order to overcome the additional
beam attenuation and keep the focal pressure above the
activation threshold, the potential for prefocal activation
at the skin should actually be smaller, since the ultrasound
pressure field is much smaller further from the focus.
Finally, it is also worth noting that phase-change nano-
droplets can be formulated with identical excipients to
FDA-approved microbubbles, which might be advanta-
geous to the eventual clinical translation of such nano-
droplet technology.
Conclusion
We have shown that HIFU-mediated liver ablation can
be significantly enhanced with mixed perfluorocarbon
nanodroplets compared to HIFU alone. In addition, data
suggested that although microbubbles could also en-
hance HIFU ablation, they resulted in unintended prefo-
cal thermal delivery and skin burns. These experiments
highlight the benefit of an agent to enhance HIFU delivery
that converts to a microbubble only at the acoustic focus,
such as a phase-change agent. Furthermore, data supports
the argument that an agent with an activation threshold
tuned to match the delivered focal acoustic pressure can
provide a mechanism for keeping thermal delivery en-
hancement to a spatially selected region of interest, as de-
termined by the pressure field and vaporization threshold
of the agent. From these data, we conclude that phase-
change nanodroplets may potentially make MR-guided fo-
cused ultrasound surgery safer and shorten procedure
times by enhancing ablation speed and volume. Future
studies will investigate the ability of these nanodroplets to
enhance HIFU ablation in vivo in a tumor model.Abbreviations
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